63 related articles for article (PubMed ID: 36368007)
1. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
[TBL] [Abstract][Full Text] [Related]
2. N-Succinimidyl 3-((4-(4-[(18)F]fluorobutyl)-1H-1,2,3-triazol-1-yl)methyl)-5-(guanidinomethyl)benzoate ([(18)F]SFBTMGMB): a residualizing label for (18)F-labeling of internalizing biomolecules.
Vaidyanathan G; McDougald D; Choi J; Pruszynski M; Koumarianou E; Zhou Z; Zalutsky MR
Org Biomol Chem; 2016 Jan; 14(4):1261-71. PubMed ID: 26645790
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the development of
Munekane M; Fuchigami T; Ogawa K
Anal Sci; 2024 May; 40(5):803-826. PubMed ID: 38564087
[TBL] [Abstract][Full Text] [Related]
4.
Yssartier T; Liu L; Pardoue S; Le Questel JY; Guérard F; Montavon G; Galland N
RSC Med Chem; 2024 Jan; 15(1):223-233. PubMed ID: 38283213
[No Abstract] [Full Text] [Related]
5. Site-Specific Radiohalogenation of a HER2-Targeted Single-Domain Antibody Fragment Using a Novel Residualizing Prosthetic Agent.
Feng Y; Sarrett SM; Meshaw RL; Vaidyanathan G; Cornejo MA; Zeglis BM; Zalutsky MR
J Med Chem; 2022 Nov; 65(22):15358-15373. PubMed ID: 36368007
[TBL] [Abstract][Full Text] [Related]
6. Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.
Feng Y; Zhou Z; McDougald D; Meshaw RL; Vaidyanathan G; Zalutsky MR
Nucl Med Biol; 2021 Jan; 92():171-183. PubMed ID: 32448731
[TBL] [Abstract][Full Text] [Related]
7. Site-Specific and Residualizing Linker for
Zhou Z; Meshaw R; Zalutsky MR; Vaidyanathan G
J Nucl Med; 2021 Nov; 62(11):1624-1630. PubMed ID: 33637584
[TBL] [Abstract][Full Text] [Related]
8. Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.
Choi J; Vaidyanathan G; Koumarianou E; Kang CM; Zalutsky MR
Nucl Med Biol; 2018 Jan; 56():10-20. PubMed ID: 29031230
[TBL] [Abstract][Full Text] [Related]
9. Labeling Single Domain Antibody Fragments with Fluorine-18 Using 2,3,5,6-Tetrafluorophenyl 6-[
Zhou Z; McDougald D; Devoogdt N; Zalutsky MR; Vaidyanathan G
Mol Pharm; 2019 Jan; 16(1):214-226. PubMed ID: 30427188
[TBL] [Abstract][Full Text] [Related]
10. Fluorine-18 labeling of an anti-HER2 VHH using a residualizing prosthetic group via a strain-promoted click reaction: Chemistry and preliminary evaluation.
Zhou Z; Chitneni SK; Devoogdt N; Zalutsky MR; Vaidyanathan G
Bioorg Med Chem; 2018 May; 26(8):1939-1949. PubMed ID: 29534937
[TBL] [Abstract][Full Text] [Related]
11. Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose
Feng Y; Meshaw R; Zhao XG; Jannetti S; Vaidyanathan G; Zalutsky MR
J Nucl Med; 2023 Jan; 64(1):124-130. PubMed ID: 35618478
[TBL] [Abstract][Full Text] [Related]
12. Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors.
Anami Y; Otani Y; Xiong W; Ha SYY; Yamaguchi A; Rivera-Caraballo KA; Zhang N; An Z; Kaur B; Tsuchikama K
Cell Rep; 2022 May; 39(8):110839. PubMed ID: 35613589
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]